The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S20-S29 , June 2008

Initiating and Intensifying Insulin Therapy in Type 2 Diabetes Mellitus

  • Joseph Tibaldi, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Joseph Tibaldi, MD, Queens Diabetes and Endocrinology Associates, 59-45 161 Street, Flushing, New York 11365, USA.

References 

  1. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdfAccessed April 18, 2008
  2. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control, 2001. Endocr Pract. 2002;8(suppl 1):5–11Available at: http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf. Accessed March 14, 2007
  3. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30(suppl1):S4–S41
  4. ACE/AACE Diabetes Road Map Task Force, 2007. Road maps to achieve glycemic control in type 2 diabetes mellitus [ACE/AACE Diabetes Recommendations Implementation Conference; AACE Website]. Endocr Pract. 2007;13:260–268Available at: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf. Accessed April 17, 2007
  5. Peyrot M, Rubin RR, Lauritzen T, et al. International DAWN Advisory Panel Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679
  6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18–S24
  7. UK Prospective Diabetes Study Group 16. Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetesz. 1995;44:1249–1258
  8. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [published correction appears in N Engl J Med. 2007;356:1387–1388] N Engl J Med. 2006;355:2427–2443
  9. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804–812
  10. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;15:2563–2569287
  11. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167
  12. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ. 2000;321:405–412
  13. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med. 2006;145:665–675
  14. Riddle MC, Rosenstock J, Gerich J Insulin Glargine 4002 Study Investigators. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  15. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–1581
  16. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274
  17. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486–496
  18. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26:1498–1505
  19. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig. 2006;26:367–401
  20. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab. 2006;8:39–48
  21. Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs. 2006;6:297–304
  22. Standl E, Maxeiner S, Raptis S HOE901/4009 Study Group. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res. 2006;38:172–177
  23. Eliaschewitz FG, Calvo C, Valbuena H, et al. HOE 901/4013 LA Study Group Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006;37:495–501
  24. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 Study). Diabetes Obes Metab. 2006;8:58–66
  25. Raskin P, Allen E, Hollander P, et al. INITIATE study group Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  26. Malone JK, Kerr LF, Campaigne BN, et al. Lispro Mixture-Glargine Study Group Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. [published correction appears in Clin Ther. 2005;27:1112] Clin Ther. 2004;26:2034–2044
  27. Sun P, Wang R, Jacober SJ. Therapeutic effectiveness of two insulin regimens for insulin naive patients with type 2 diabetes mellitus: once-daily basal insulin or twice-daily premixed insulin?. Diabetes. 2006;55(suppl 1):Abstract 427-P
  28. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med. 2005;22:374–381
  29. Rolla A. The pathophysiological basis for intensive insulin replacement. Int J Obes Relat Metab Disord. 2004;28(suppl 2):S3–S7
  30. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res. 2004;36:775–781
  31. Middelbeek RJ, Horton ES. The role of glucose as an independent cardiovascular risk factor. Curr Diab Rep. 2007;7:43–49
  32. Monnier L, Colette C, Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12(suppl 1):42–46
  33. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007;77:1–15
  34. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443–445
  35. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498–1504
  36. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290–299
  37. Fritsche A, Schweitzer MA, Haring HU 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003;138:952–959
  38. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189–196
  39. Kennedy L, Herman WH, Strange P, Harris A GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1–8
  40. Yki-Jarvinen H, Kauppinen-Makelin R, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442–451
  41. Rašlová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27:279–285
  42. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418–427
  43. Davies M, Storms F, Shutler S, et al. ATLANTUS Study Group Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–1288
  44. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17:307–313
  45. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract. 2006;72:265–270
  46. BIAsp-3021 Study GroupWan MW. Adding NovoLog® Mix 70/30 once or twice daily is more efficacious than optimizing oral treatment in patients with type 2 diabetes. [abstract] Diabetes. 2005;54(suppl 1):A510
  47. Raskin P, Braceras R, Schwartz S, Chaykin L, Chu P-L, Wynne A. Over 75% of patients with type 2 diabetes reached HbA1c <7% by adding biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment. Diabetologia. 2006;49(suppl 1):487;[abstract 803]
  48. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007;55:62–68
  49. Tibaldi J. Biphasic insulin aspart 70/30 three times a day in older patients with Type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: A retrospective case series analysis from clinical practice. Adv Ther. 2007;(24):1348–1356
  50. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia. 2006;49:1163–1168
  51. Lankisch M, Stahr B, Alawi H, Ferlinz K, Scherbaum W. Basal insulin and oral antihyperglycemic therapy (BOT) plus a single dose of insulin glulisine at breakfast or at the predominant meal lower HbA1c in patients with type 2 diabetes. Diabetes. 2006;55(suppl 1):Abstract 514-P
  52. Bergenstal RM, Johnson ML, Powers MA, Wynne AG, Vlajnic A, Hollander PA. Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on preprandial glucose patterns is a safe and effective alternative to carbohydrate counting (Carb Count). Diabetes. 2006;55(suppl 1):Abstract 441-P
  53. Liebl A, Prager R, Binz K, Kaiser M, Gallwitz B PREFER Study Group. The PREFER Study: both biphasic insulin Aspart 30 (BIAsp 30) twice-daily and basal-bolus using insulin detemir (IDet) and insulin aspart (IAsp) enabled patients with type 2 diabetes to achieve A1c target <7.0%. Diabetologia. 2006;49(suppl 1):610;[abstract 998]

 Publication of this article has been supported by Novo Nordisk Inc.

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00310-0

doi: 10.1016/j.amjmed.2008.03.023

The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S20-S29 , June 2008

Article Tools

* Image Usage & Resolution